Layoffs
Eli Lilly and Company is set to cut 163 jobs as it closes its Dermira facility in Menlo Park and sells off the latter company’s sweat drug Qbrexza, which is being snatched up by Journey Medical.
Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.
The biopharma industry remained strong, as demand for COVID-related products skyrocketed. However, some companies are facing layoffs. Here’s a brief overview.
Amgen is in the process of eliminating hundreds of U.S. jobs, the majority of which are centered on the company’s sales team, according to a recent sales call.
Less than a year after taking over the reins, Biotechnology Innovation Organization Chief Executive Officer Michelle McMurry-Heath is reorganizing the organization’s leadership structure.
DBV announced official restructuring plan for keeping the company afloat.
The recalibration will also have workforce implications, including an overall workforce reduction of approximately 20% during Q1, 2021.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
PRESS RELEASES
